Lisi Group (FII) H2 2025 earnings summary

Executive summary

• Achieved organic growth over 10% for the fourth consecutive year, with record revenue of €1,747.9 million, up 8.7% year-over-year, driven by strong aerospace market performance.

• EBIT rose 63.2% to €161.0 million, and net income reached €139.7 million, 2.5 times higher than the prior year.

• Sale of LISI MEDICAL division for €270.4 million, with reinvestment and potential earn-outs, significantly reduced net financial debt.

• Inclusion in SBF 120 and CAC Mid 60 indices reflects market confidence.

Financial highlights

• EBITDA increased 42.5% to €261.5 million, with margin up 3.6 points to 15%.

• Free cash flow was €56.1 million after €99.9 million in net industrial investments.

• Net financial debt dropped to €233.7 million (0.9x EBITDA), down from €488.5 million (2.3x EBITDA) in 2024.

• Dividend proposed at €0.46 per share, up from €0.39.

Outlook and guidance

• Aerospace order book supports continued growth in 2026; focus on improving operating income and generating positive free cash flow, assuming stable macroeconomic conditions.

• Automotive division to continue cost structure adaptation and product repositioning amid market uncertainty.